Focus Partners Advisor Solutions LLC Buys 3,367 Shares of Eli Lilly and Company $LLY

Key Points

• Focus Partners Advisor Solutions LLC increased its stake in Eli Lilly and Company by 27.7%, holding shares worth approximately $12.80 million as of the latest SEC filing.
• Equity analysts have downgraded Eli Lilly from "buy" to "hold" or "neutral", with target price estimates ranging from $700.00 to $1,135.00 for the stock.
• Eli Lilly reported earnings of $6.31 per share, exceeding estimates, with a net margin of 25.91% and revenue growth of 37.6% year-over-year.

Focus Partners Advisor Solutions LLC grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 27.7% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,502 shares of the company's stock after purchasing an additional 3,367 shares during the quarter. Focus Partners Advisor Solutions LLC's holdings in Eli Lilly and Company were worth $12,803,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Corient IA LLC bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $570,000. LS Investment Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 1.7% in the 1st quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares in the last quarter. Prism Advisors Inc. bought a new stake in Eli Lilly and Company during the 1st quarter valued at $207,000. Hemington Wealth Management raised its holdings in Eli Lilly and Company by 14.4% during the first quarter. Hemington Wealth Management now owns 985 shares of the company's stock worth $813,000 after buying an additional 124 shares during the last quarter. Finally, Bfsg LLC raised its holdings in Eli Lilly and Company by 1.4% during the first quarter. Bfsg LLC now owns 2,959 shares of the company's stock worth $2,444,000 after buying an additional 42 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other news, CEO David A. Ricks purchased 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the business's stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company's stock, valued at $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Insiders purchased a total of 4,514 shares of company stock worth $2,894,841 in the last 90 days. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $1.08 during trading hours on Wednesday, hitting $736.27. 2,220,178 shares of the company were exchanged, compared to its average volume of 6,612,480. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $696.85 billion, a price-to-earnings ratio of 45.36, a P/E/G ratio of 1.02 and a beta of 0.47. The firm has a fifty day simple moving average of $747.03 and a 200 day simple moving average of $783.75. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $954.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company's revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.8%. Eli Lilly and Company's payout ratio is 39.22%.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a report on Thursday, June 5th. HSBC upgraded Eli Lilly and Company from a "reduce" rating to a "hold" rating and lifted their price target for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. UBS Group decreased their price objective on Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating for the company in a report on Friday, August 8th. Cantor Fitzgerald dropped their target price on Eli Lilly and Company from $975.00 to $825.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Finally, Guggenheim cut their target price on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $950.17.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.